Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Sep;43(9):709-717.
doi: 10.1007/s40261-023-01299-y. Epub 2023 Aug 22.

OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers

Yu Bagger  1 , William R Ravis  2 , Geoff Harris  2 , Stan Bukofzer  3
Affiliations
Clinical Trial

OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers

Yu Bagger et al. Clin Drug Investig. 2023 Sep.

Abstract

Background: OCE-205, a novel, selective vasopressin V1a receptor mixed agonist/antagonist with no V2 receptor activity, may treat the portal hypertension-related complications of end-stage liver disease with an improved therapeutic profile over currently utilized nonselective full-agonist vasopressin analogs.

Objectives: This Phase 1, double-blind, placebo-controlled, within-dose-group randomized trial investigated the safety, tolerability, and pharmacokinetic/pharmacodynamic profiles of OCE-205 in healthy adults.

Methods: Subjects received a single intravenous dose of OCE-205 0.1, 0.3, 0.45, 0.6, or 0.9 mg, or placebo infused over 6 h. Safety and tolerability were assessed, and blood samples were obtained for pharmacokinetic analyses. Sixty-four subjects were randomized and treated.

Results: Area under the concentration-time curve (AUC) and maximum plasma concentrations (Cmax) were approximately dose-proportional across doses from 0.1 to 0.9 mg. OCE-205 terminal half-life was ~ 1.5 h. Diastolic, and to a lesser extent systolic, blood pressure increased in all OCE-205 dose groups; pulse rate decreased. Overall changes in mean arterial pressure were similar to changes in diastolic blood pressure. Absolute changes in cardiac output, by echocardiogram, were somewhat dose-dependent, with mean reductions of 3-12% after the 0.9 mg dose, and individual reductions ≤ 20 to 25% across all doses. The most frequent adverse events were abdominal pain, abnormal gastrointestinal sounds, and diarrhea, with no reported cases of mesenteric ischemia. Adverse events were generally mild or moderate in severity.

Conclusion: OCE-205 was safe and well tolerated, with a pharmacodynamic profile achieving submaximal partial agonism consistent with mixed agonism-antagonism of the V1a receptor. OCE-205 shows promise as a treatment for some complications of end-stage liver disease.

PubMed Disclaimer

Conflict of interest statement

Stan Bukofzer and Geoff Harris are founders of Ocelot Bio, Inc; Stan Bukofzer, Geoff Harris, and William R. Ravis are consultants/advisors to Ocelot Bio, Inc. Yu Bagger was an employee of Ferring Pharmaceuticals A/S at the time of the study.

Figures

Fig. 1
Fig. 1
Time course of OCE-205 concentration after intravenous infusion. LLOQ lower limit of quantitation. Values are mean ± standard error
Fig. 2
Fig. 2
Mean (SD) arterial pressure after intravenous infusion. Mean arterial pressure data were measured every 30 min after administration, but are plotted offset on the x-axis for clarity of presentation
See this image and copyright information in PMC

References

    1. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014–1048. doi: 10.1002/hep.31884. - DOI - PubMed
    1. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105(1):229–236. doi: 10.1016/0016-5085(93)90031-7. - DOI - PubMed
    1. Gines P, Sola E, Angeli P, Wong F, Nadim MK, Kamath P. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4(1):23. doi: 10.1038/s41572-018-0022-7. - DOI - PubMed
    1. Harper D, Chandler B. Splanchnic circulation. BJA Educ. 2016;16:66–71. doi: 10.1093/bjaceaccp/mkv017. - DOI
    1. Moller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int. 2018;38(4):570–580. doi: 10.1111/liv.13589. - DOI - PubMed

Publication types